The KEYNOTE 407 phase III study was dedicated to squamous NSCLC, treatment naïve patients and it demonstrated that pembrolizumab combined with chemotherapy is associated with longer median OS (15.9 months in pembrolizumab treated group and 11.3 in chemotherapy alone treated group, HR = 0.64), regardless of PD-L1 expression on tumor cells. The gene discussed is CD274; the disease is non-small cell lung carcinoma.